Cholecystokinin input from the anterior cingulate cortex to the lateral periaqueductal gray mediates nocebo pain behavior in mice

This study identifies a shared neural circuit involving cholecystokinin projections from the anterior cingulate cortex to the lateral periaqueductal gray that mediates nocebo-induced pain hypersensitivity in mice, offering a potential therapeutic target for pain-related disorders.

The Gist

The "Evil Twin" of the Placebo Effect

You've probably heard of the placebo effect: if you believe a sugar pill will cure your headache, your brain might actually release natural painkillers, and the pain goes away. It's the power of positive thinking.

This paper is about the "nocebo effect," which is the evil twin. This happens when you expect something to hurt, or you see someone else in pain, and your brain makes the pain feel much worse than it actually is. It's like your brain putting on "pain goggles" that make a paper cut feel like a knife wound.

For a long time, scientists knew that a chemical called Cholecystokinin (CCK) was involved in this in humans, but they didn't know where in the brain this was happening or how it worked. They needed a mouse model to figure it out.

The Experiment: Teaching Mice to Worry

The researchers used two different ways to make mice "expect" pain:

1. The "Haunted House" (Contextual Nocebo): They gave a mouse a tiny, painful cut on its paw. While the mouse was recovering, they left it in a specific room with a distinct smell and texture. Later, when the cut was healed, they put the mouse back in that same room. Even though the mouse wasn't hurt anymore, just being in that "pain room" made its paw feel super sensitive again.
2. The "Empathy" Effect (Social Nocebo): They put a mouse next to a friend who was currently in pain (from a chemical injection). The observer mouse watched its friend suffer. Afterward, the observer mouse was tested and found to be much more sensitive to pain, even though it had never been hurt itself.

The Big Discovery: In both cases, the mice's brains were flooding with CCK. When the scientists gave the mice a drug to block CCK (like turning off a radio signal), the "worry" disappeared, and the mice stopped feeling extra pain.

The Neural Circuit: The "Pain Amplifier"

The most exciting part of this paper is finding the specific "wiring" in the brain that causes this. The researchers found a direct line between two specific areas:

1. The Anterior Cingulate Cortex (ACC): Think of this as the brain's "Worry Manager." It's the part that processes fear, anxiety, and social cues. It's where the mouse thinks, "Oh no, I'm in the pain room," or "Oh no, my friend is hurting."
2. The Lateral Periaqueductal Gray (lPAG): Think of this as the brain's "Pain Volume Knob." It's a deep structure that controls how loud or quiet pain signals feel.

The Analogy:
Imagine your brain is a home theater system.

• The ACC is the person sitting in the control booth who sees a scary movie trailer (the expectation of pain).
• The lPAG is the massive speaker system.
• CCK is the specific cable connecting the booth to the speakers.

When the "Worry Manager" (ACC) sees a threat, it sends a signal down the CCK cable to the Volume Knob (lPAG). This turns the volume up to 11, making a tiny noise (a small pain) sound like a deafening explosion.

How They Proved It

The scientists used high-tech tools to prove this connection:

• Cutting the Wire: They used a special virus to "silence" the CCK neurons in the Worry Manager. When they did this, the mice stopped feeling the extra pain. The "volume knob" stayed at zero.
• Turning the Volume Up: They used light (optogenetics) to artificially zap the CCK neurons. Suddenly, the mice felt intense pain even though nothing was hurting them. They had manually turned the volume knob up.
• The "Worry" vs. "Real Danger" Test: They also tested the mice with a predator smell (like a fox). This causes real, immediate fear. Interestingly, blocking CCK didn't stop the reaction to the fox. This proves that CCK is specifically for expectation-based pain (the "what if" scenario), not for immediate, life-or-death danger.

Why This Matters

This is a huge breakthrough for a few reasons:

1. It explains the "Mind-Body" link: It shows exactly how a thought (expecting pain) physically changes how your body feels pain.
2. New Treatments: Since we know this specific "CCK cable" is the culprit, doctors might be able to develop drugs that block just this pathway. This could help people who suffer from chronic pain that gets worse because they are anxious about it, without making them feel numb or sedated.
3. Social Pain: It proves that pain is contagious. When we see others suffer, our brains literally rewire to feel more pain ourselves, and this study shows the biological mechanism behind that empathy.

In short: Your brain has a specific "pain amplifier" that gets turned on when you are worried or see others in pain. This paper found the exact wire (CCK) that connects your worry center to your pain center, and showed that cutting that wire stops the extra pain.

Technical Summary

1. Problem Statement

The nocebo effect—where negative expectations exacerbate pain and symptoms—is a significant clinical challenge, often leading to poor therapeutic outcomes. In humans, nocebo hyperalgesia is known to be mediated by the neuropeptide cholecystokinin (CCK), as it can be blocked by the CCK receptor antagonist proglumide. However, the specific neural circuitry underlying this phenomenon has remained unidentified due to a lack of appropriate animal models. While both environmental conditioning and social observation can induce nocebo effects, it was unclear whether these distinct pathways converge on a shared neural mechanism involving CCK.

2. Methodology

The study utilized a multi-modal approach combining two independent laboratories' animal models with advanced neurobiological techniques:

• Animal Models:
  • Contextual Nocebo: Mice were conditioned to associate a specific environmental context with a painful stimulus (hind paw incision or chronic constriction injury [CCI]). Re-exposure to the context without the actual injury induced pain hypersensitivity.
  • Social Nocebo: Naïve "Observer" mice interacted with "Demonstrator" mice experiencing pain (formalin injection). Observers subsequently exhibited heightened pain sensitivity.
• Pharmacology: Systemic and local (intracerebral) administration of CCK receptor antagonists (non-specific proglumide and selective CCK-2 antagonist LY 225910) to test necessity. Local infusion of CCK-8S (agonist) to test sufficiency.
• Anatomical Tracing & Imaging:
  • Retrograde Tracing: Used Cre-dependent retrograde AAVs in CCK-IRES-Cre mice to map projections to the periaqueductal gray (PAG).
  • Immunohistochemistry (c-Fos): Quantified neuronal activation in the PAG across rostrocaudal axes.
  • RNAscope: Quantified co-localization of Fos (activation marker) and Cckbr (CCK-2 receptor) transcripts in the PAG.
  • Spatial Transcriptomics: Analyzed the Allen Brain Cell Atlas to characterize the molecular identity of Cckbr-expressing neurons.
• Circuit Manipulation:
  • Chemogenetics (DREADDs): Silenced CCK-expressing neurons in the Anterior Cingulate Cortex (ACC) or excitatory neurons generally.
  • Optogenetics: Used CCK-IRES-Cre mice to express inhibitory opsins (eOPN3) or excitatory opsins (ChR2) in ACC neurons projecting to the lateral PAG (lPAG). This allowed for projection-specific inhibition or activation during behavioral testing.

3. Key Contributions

• Identification of a Specific Circuit: The study identifies a previously unrecognized pathway: CCKergic projections from the Anterior Cingulate Cortex (ACC) to the intermediate Lateral Periaqueductal Gray (lPAG).
• Convergence of Paradigms: Demonstrates that both environmentally conditioned and socially transmitted nocebo effects rely on the same neural circuit and CCK-2 receptor signaling.
• Cellular Specificity: Characterizes the target neurons in the lPAG as a specific subset of glutamatergic neurons (marked by Pou4f1) that co-express mu-opioid (Oprm1) and cannabinoid (Cnr1) receptors, distinct from stress-related CRH neurons.
• Mechanistic Distinction: Establishes that this CCK pathway is specific to expectancy-driven pain amplification and is not a general mediator of stress-induced hyperalgesia (as shown by predator threat experiments).

4. Key Results

Behavioral & Pharmacological Findings

• Both contextual and social nocebo paradigms induced robust mechanical and thermal hypersensitivity.
• This hypersensitivity was blocked by systemic administration of proglumide and the selective CCK-2 antagonist LY 225910.
• Crucially, CCK antagonism did not affect baseline pain sensitivity, acute injury pain, or stress-evoked hypersensitivity induced by predator odor (TMT), indicating the pathway is specific to negative expectation rather than general stress.

Anatomical & Circuit Mapping

• PAG Activation: Both nocebo paradigms increased c-Fos expression specifically in the intermediate lPAG (and dorsomedial/dorsolateral columns), but not in the anterior or posterior PAG.
• Receptor Specificity: Microinfusion of proglumide into the intermediate lPAG blocked nocebo hypersensitivity, whereas infusion into the dorsomedial PAG (dmPAG) had no effect. Conversely, CCK-8S infusion into the lPAG was sufficient to induce pain hypersensitivity.
• Source Identification: Retrograde tracing revealed that the primary source of CCK projections to the intermediate lPAG is the Anterior Cingulate Cortex (ACC), specifically layer V pyramidal neurons.
• Molecular Identity: RNAscope and transcriptomic data showed that nocebo-induced activation in the lPAG recruits Cckbr-expressing glutamatergic neurons. In contextual nocebo, low-to-moderate Cckbr expressing cells were recruited, while social nocebo recruited cells with high Cckbr abundance.

Causal Manipulation (Optogenetics/Chemogenetics)

• Necessity: Chemogenetic silencing of ACC CCK neurons blocked contextual nocebo. Optogenetic inhibition of ACC→lPAG CCK terminals blocked both contextual and social nocebo hypersensitivity.
• Sufficiency: Optogenetic activation of ACC→lPAG CCK terminals was sufficient to induce rapid mechanical hypersensitivity, which was reversed by lPAG proglumide infusion.
• Timing: Inhibiting the pathway during the conditioning phase did not prevent learning, but inhibiting it during the expression/retrieval phase blocked the behavior. This suggests the circuit is required for the expression of the nocebo effect, not the acquisition of the association.

5. Significance

• Translational Relevance: The findings provide a direct neural mechanism for the human observation that proglumide blocks nocebo hyperalgesia. By identifying the ACC-lPAG circuit, the study offers a concrete target for therapeutic intervention in pain disorders exacerbated by negative expectations.
• Differentiation from Placebo: The study clarifies that while placebo analgesia relies on opioid-dependent pathways (often involving the ventrolateral PAG), nocebo hyperalgesia relies on a CCK-dependent pathway in the intermediate lPAG. This suggests that positive and negative expectations bias a shared ACC-PAG circuit toward inhibitory (opioid) or facilitatory (CCK) outputs, respectively.
• Clinical Implications: Understanding that nocebo effects are mediated by a specific, modifiable circuit (rather than a generalized stress response) opens avenues for developing targeted pharmacological or neuromodulatory therapies to mitigate nocebo effects in clinical settings, potentially improving pain management outcomes.